The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
The SARTAN-AD trial, sponsored by Sunnybrook Health Sciences Centre, aimed to explore the potential of repurposing Telmisartan, an angiotensin receptor blocker (ARB), as a neuroprotective agent in mild to moderate Alzheimer's Disease (AD) patients. The study's termination due to recruitment challenges highlights the difficulties in enrolling participants for Alzheimer's trials, a common issue in this therapeutic area. Should the proof of concept yield positive results, it could pave the way for larger studies, potentially altering treatment paradigms for AD and expanding market opportunities for Telmisartan and Perindopril in this indication. The competitive landscape includes established AD therapies and emerging candidates, necessitating a thorough assessment of clinical efficacy and safety profiles to ensure differentiation.
Indication: Alzheimer's Disease
Modality: small molecule
Target: Angiotensin II receptor (AT1 receptor) modulation via Telmisartan and Angiotensin-converting enzyme inhibition via Perindopril.
Sponsor: Sunnybrook Health Sciences Centre
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Angiotensin II receptor (AT1 receptor) modulation via Telmisartan and Angiotensin-converting enzyme inhibition via Perindopril.
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Angiotensin II receptor (AT1 receptor) modulation via Telmisartan and Angiotensin-converting enzyme inhibition via Perindopril.
Target normalized: Angiotensin II receptor (AT1 receptor) modulation via Telmisartan and Angiotensin-converting enzyme inhibition via Perindopril.